MMAE-d8
Based on 10 publication(s) in Google Scholar
MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
For research use only. We do not sell to patients.
- Purity: 99.15%
- CAS No.: 2070009-72-0
- Formula: C39H59D8N5O7
- Molecular Weight:726.03
-
Storage:Powder -20°C, 3 years , 4°C, 2 years
* The compound is unstable in solutions, freshly prepared is recommended.
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MMAE-d8
More- Signal Transduct Target Ther. 2025 Sep 24;10(1):316. [Abstract]
- J Pharm Anal. 2022 Aug;12(4):645-652. [Abstract]
- Pharmaceutics. 2025 Mar 17;17(3):377. [Abstract]
- Mol Cancer Ther. 2023 Apr 3;22(4):459-470. [Abstract]
- Drug Metab Dispos. 2017 Nov;45(11):1120-1132. [Abstract]
- AAPS J. 2021 Apr 15;23(3):56. [Abstract]
- J Pharm Biomed Anal. 2024 Jun 19:248:116318. [Abstract]
- Patent. US20220356169A1.
- Patent. US20220184222A1.
- Technische Universitat Darmstadt. 2022 Feb.
Biological Activity
|
Auristatin |
Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads. ADCs are generated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and the intracellular concentration of released MMAE correlated with in vitro ADC-mediated cytotoxicity independent of target expression or drug:antibody ratios. LC-MS is used to measure the concentration of MMAE in a parallel cohort of L-82 tumors with an identical treatment regimen. Although tumor volume is not different among treatment groups 3 days after dose, the intratumoral MMAE measurement reveals two patterns. First, intratumoral MMAE concentration increases proportionally to the ADC dose, which correspondes to stronger antitumor activity. Second, the intratumoral MMAE concentration obtained from treatment with both cOKT9-vcMMAE and cAC10-vcMMAE is similar at each dose, consistent with the observation that tumor responded similarly to these two ADCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 2070009-72-0
-
Unlabeled Cas 474645-27-7
-
Appearance Solid
-
Molecular Weight 726.03
-
Formula C39H59D8N5O7
-
Color White to off-white
-
SMILES
O=C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1[C@H]([C@H](OC)[C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)CCC1)=O)C)[C@@]([2H])(NC([C@@H](NC)C(C)C)=O)C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H]
-
Synonyms
Monomethyl auristatin E-d8; Deuterated labeled MMAE
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years * The compound is unstable in solutions, freshly prepared is recommended.
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
An aptamer-drug conjugate for promising cancer therapy with comprehensive evaluation from rodents to non-human primates. [Abstract]2025 Sep 24;10(1):316. PMID: 40987771 -
J Pharm Anal
Enzyme-linked immunosorbent assays for quantification of MMAE-conjugated ADCs and total antibodies in cynomolgus monkey sera. [Abstract]2022 Aug;12(4):645-652. PMID: 36105165 -
Pharmaceutics
2025 Mar 17;17(3):377. PMID: 40143040 -
Mol Cancer Ther
Payload-binding Fab fragments increase the therapeutic index of MMAE antibody-drug conjugates. [Abstract]2023 Apr 3;22(4):459-470. PMID: 36723609 -
Drug Metab Dispos
Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE. [Abstract]2017 Nov;45(11):1120-1132. PMID: 28821484 -
AAPS J
Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor. [Abstract]2021 Apr 15;23(3):56. PMID: 33856579 -
J Pharm Biomed Anal
Development and validation of bioanalytical assays for the quantification of 9MW2821, a nectin-4-targeting antibody-drug conjugate. [Abstract]2024 Jun 19:248:116318. PMID: 38908237 -
-
-
Solvent & Solubility
DMSO : 100 mg/mL (137.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cell pellets are collected 24 hours after ADC treatment. Cell count, diameter, and circularity are determined on Vi-Cell Counter. MMAE extraction and quantification method is performed. Briefly, tumors or cell pellets are homogenized with methanol and acetonitrile containing internal standard (d8-MMAE for MMAE detection and 13C-MMAF for MMAF detection). The homogenates are centrifuged at 10,000 rpm to precipitate protein and protein-bound payloads. The supernatant is then subjected to solid phase extraction, and signals of MMAE and MMAF are detected by LC-MS[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (645 KB)
- English - EN (645 KB)
- Français - FR (645 KB)
- Deutsch - DE (645 KB)
- Norwegian - NO (645 KB)
- Español - ES (645 KB)
- Swedish - SV (645 KB)
- Italian - IT (645 KB)
- Korean - KR (645 KB)
- Portuguese - PT (645 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3774 mL | 6.8868 mL | 13.7735 mL | 34.4338 mL |
| 5 mM | 0.2755 mL | 1.3774 mL | 2.7547 mL | 6.8868 mL | |
| 10 mM | 0.1377 mL | 0.6887 mL | 1.3774 mL | 3.4434 mL | |
| 15 mM | 0.0918 mL | 0.4591 mL | 0.9182 mL | 2.2956 mL | |
| 20 mM | 0.0689 mL | 0.3443 mL | 0.6887 mL | 1.7217 mL | |
| 25 mM | 0.0551 mL | 0.2755 mL | 0.5509 mL | 1.3774 mL | |
| 30 mM | 0.0459 mL | 0.2296 mL | 0.4591 mL | 1.1478 mL | |
| 40 mM | 0.0344 mL | 0.1722 mL | 0.3443 mL | 0.8608 mL | |
| 50 mM | 0.0275 mL | 0.1377 mL | 0.2755 mL | 0.6887 mL | |
| 60 mM | 0.0230 mL | 0.1148 mL | 0.2296 mL | 0.5739 mL | |
| 80 mM | 0.0172 mL | 0.0861 mL | 0.1722 mL | 0.4304 mL | |
| 100 mM | 0.0138 mL | 0.0689 mL | 0.1377 mL | 0.3443 mL |
Powered by Bioz